Cargando…

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review

The prognosis of patients with relapsed/refractory NK/T-cell lymphoma (NKTCL) is dismal. Immunotherapy has showed encouraging anti-tumor activity in patients with asparaginase-resistant NKTCL; however, only a portion of patients benefit and the median response duration is rather short. Treatment str...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zheng, Yao, Shuna, Liu, Yanyan, Zhang, Jianbo, Li, Peng, Wang, Haiying, Chu, Junfeng, Zhao, Shuang, Yao, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759664/
https://www.ncbi.nlm.nih.gov/pubmed/33363038
http://dx.doi.org/10.3389/fonc.2020.608304
_version_ 1783627154324455424
author Yan, Zheng
Yao, Shuna
Liu, Yanyan
Zhang, Jianbo
Li, Peng
Wang, Haiying
Chu, Junfeng
Zhao, Shuang
Yao, Zhihua
author_facet Yan, Zheng
Yao, Shuna
Liu, Yanyan
Zhang, Jianbo
Li, Peng
Wang, Haiying
Chu, Junfeng
Zhao, Shuang
Yao, Zhihua
author_sort Yan, Zheng
collection PubMed
description The prognosis of patients with relapsed/refractory NK/T-cell lymphoma (NKTCL) is dismal. Immunotherapy has showed encouraging anti-tumor activity in patients with asparaginase-resistant NKTCL; however, only a portion of patients benefit and the median response duration is rather short. Treatment strategies have not been identified for immunotherapy-resistant NKTCL. We describe a patient with primary cutaneous NKTCL experienced disease progression after pegaspargase-based chemotherapy and PD-1 inhibitor (sintilimab)-based immunotherapy. Following a combined treatment of sintilimab and the HDAC inhibitor chidamide, the patient achieved a durable complete molecular response with mild toxicity. This case indicates that the combination of PD-1 inhibitor and HDAC inhibitor might be a treatment choice for immunotherapy-resistant NKTCL.
format Online
Article
Text
id pubmed-7759664
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77596642020-12-26 Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review Yan, Zheng Yao, Shuna Liu, Yanyan Zhang, Jianbo Li, Peng Wang, Haiying Chu, Junfeng Zhao, Shuang Yao, Zhihua Front Oncol Oncology The prognosis of patients with relapsed/refractory NK/T-cell lymphoma (NKTCL) is dismal. Immunotherapy has showed encouraging anti-tumor activity in patients with asparaginase-resistant NKTCL; however, only a portion of patients benefit and the median response duration is rather short. Treatment strategies have not been identified for immunotherapy-resistant NKTCL. We describe a patient with primary cutaneous NKTCL experienced disease progression after pegaspargase-based chemotherapy and PD-1 inhibitor (sintilimab)-based immunotherapy. Following a combined treatment of sintilimab and the HDAC inhibitor chidamide, the patient achieved a durable complete molecular response with mild toxicity. This case indicates that the combination of PD-1 inhibitor and HDAC inhibitor might be a treatment choice for immunotherapy-resistant NKTCL. Frontiers Media S.A. 2020-12-11 /pmc/articles/PMC7759664/ /pubmed/33363038 http://dx.doi.org/10.3389/fonc.2020.608304 Text en Copyright © 2020 Yan, Yao, Liu, Zhang, Li, Wang, Chu, Zhao and Yao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yan, Zheng
Yao, Shuna
Liu, Yanyan
Zhang, Jianbo
Li, Peng
Wang, Haiying
Chu, Junfeng
Zhao, Shuang
Yao, Zhihua
Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
title Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
title_full Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
title_fullStr Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
title_full_unstemmed Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
title_short Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
title_sort durable response to sintilimab and chidamide in a patient with pegaspargase- and immunotherapy-resistant nk/t-cell lymphoma: case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759664/
https://www.ncbi.nlm.nih.gov/pubmed/33363038
http://dx.doi.org/10.3389/fonc.2020.608304
work_keys_str_mv AT yanzheng durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT yaoshuna durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT liuyanyan durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT zhangjianbo durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT lipeng durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT wanghaiying durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT chujunfeng durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT zhaoshuang durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview
AT yaozhihua durableresponsetosintilimabandchidamideinapatientwithpegaspargaseandimmunotherapyresistantnktcelllymphomacasereportandliteraturereview